What is the recommended approach to diagnose and understand small-fiber neuropathy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Diagnosing Small Fiber Neuropathy

Diagnose small fiber neuropathy through a combination of clinical signs (at least two abnormal findings on examination) plus either abnormal quantitative sensory testing (QST) OR reduced intraepidermal nerve fiber density (IENFD) on skin biopsy—sensory symptoms alone are insufficient for diagnosis. 1

Clinical Assessment Framework

Essential Clinical Examination

Assess for small fiber dysfunction using these specific bedside tests 2, 3:

  • Small-fiber function: Pinprick sensation and temperature perception (testing Aδ and C-fiber function)
  • Large-fiber function: Vibration sensation with 128-Hz tuning fork and 10-g monofilament testing

Critical caveat: Up to 50% of small fiber neuropathy may be asymptomatic, so absence of symptoms does not exclude the diagnosis 2. Conversely, sensory symptoms without objective clinical signs are unreliable—in one validation study, 89% of such patients had normal testing and 56% experienced complete symptom resolution at follow-up 1.

Diagnostic Testing Algorithm

When clinical signs are present, proceed with:

  1. Skin biopsy for IENFD (3mm punch biopsy, typically at distal leg): This is the gold standard structural test 1, 4. IENFD correlates inversely with neuropathy severity and is reduced early in disease, even when nerve conduction studies are normal 5.

  2. Quantitative Sensory Testing (QST): Assesses thermal thresholds for heat and cold detection, reflecting small fiber function 6, 1.

Diagnostic certainty requires: At least two clinical signs PLUS abnormal QST and/or abnormal IENFD 1. The combination approach is critical—patients with only one abnormal test (either QST or IENFD) without clinical signs did not develop confirmed small fiber neuropathy at 18-month follow-up 1.

Autonomic Testing Considerations

When autonomic symptoms are prominent (orthostatic dizziness, gastroparesis, sudomotor dysfunction), add:

  • Quantitative sudomotor axon reflex test (QSART): Assesses postganglionic sudomotor function
  • Thermoregulatory sweat testing: Highly sensitive for small fiber neuropathy (abnormal in ~90% of cases) 7

Important distinction: Electrophysiological testing (EMG/NCS) is typically normal in pure small fiber neuropathy and is used primarily to exclude large fiber involvement 6, 4. Referral to neurology is only needed when clinical features are atypical or diagnosis remains unclear 2, 3.

Etiological Workup

Small fiber neuropathy is a diagnosis of exclusion—always investigate underlying causes 2, 3, 2:

First-Tier Laboratory Screening

Order these tests universally 8:

  • Hemoglobin A1c and fasting glucose (diabetes/prediabetes)
  • Vitamin B12 level
  • Thyroid-stimulating hormone
  • Complete blood count
  • Basic metabolic panel

Second-Tier Testing (when first-tier negative)

Consider based on clinical context 3:

  • Serum protein electrophoresis (monoclonal gammopathy)
  • HIV testing
  • Hepatitis C serology
  • Antinuclear antibody and inflammatory markers (autoimmune causes)
  • Heavy metal screening if exposure suspected
  • Genetic testing for hereditary neuropathies (especially SCN9A mutations in familial cases) 7

Common pitfall: Approximately 50% of cases remain idiopathic despite thorough workup 6. Avoid over-testing with low-yield panels—paraneoplastic antibodies showed significant practice variation (35-52% ordering rates) but limited diagnostic utility in routine small fiber neuropathy evaluation 8.

Diagnostic Criteria Summary

Definite small fiber neuropathy: ≥2 clinical signs + abnormal QST and/or reduced IENFD 1

Probable small fiber neuropathy: ≥2 clinical signs + abnormal QST + abnormal IENFD but no clinical signs (these patients typically develop signs within 18 months) 1

Not small fiber neuropathy: Sensory symptoms alone with normal examination, normal QST, and normal IENFD 1

The strength of this diagnostic approach lies in its validation through prospective follow-up studies demonstrating that the combined clinical-functional-structural assessment reliably identifies true small fiber neuropathy while avoiding false-positive diagnoses in patients with transient sensory complaints 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.